Since NSC1892 specifically targeted the CUL4A/4B-DDB1 interactions, we speculated that it should also be effective to inhibit the cell growth of other CUL4A- or CUL4B-overexpression tumor cells, not only CRC cells. The gene discussed is DDB1; the disease is neoplasm.